Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Amphastar Pharmaceuticals, Inc. reported revenue of $720M, down 1.7% year over year. Operating margin was 19.5% and net margin 13.6%, on a free-cash-flow margin of 16.8% with capital expenditure at 4.8% of revenue. Every figure is computed directly from AMPH's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $720M | 19.5% | 13.6% |
| FY2024 | $732M | 28.1% | 21.8% |
| FY2023 | $644M | 30.6% | 21.3% |
| FY2022 | $499M | 21.5% | 18.3% |
| FY2021 | $438M | 16.0% | 14.2% |
How does AMPH compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.